- Home
- Companies
- TriNetX, LLC
- Software
- TriNetX - Platform for Global Oncology
TriNetX - Platform for Global Oncology
Drawing on clinical and registry partnerships from around the globe, TriNetX provides real-world data that combines histology, genomic variants, and other biomarkers with treatment, line change, and survival records, so your research can run deeper.
Staging, biomarkers, and more from CTR-curated registries
Our partnerships with cancer registries around the world let us bring together a large and growing volume of primary site, histology, staging, and biomarker data.
Genomic data from hospitals and external laboratories
We source mutation and variant data from a cross section of genomic laboratories, for richer genetic profiles on a more diverse patient population.
Granular EHR and lab data, pre- and post-cancer
Detailed EHR data and lab results, from before diagnosis and after treatment, open new avenues of research into risks, treatment planning, and prognoses.
Academic and community hospitals from around the world
In our data, you’ll find the latest immunologic treatments for rare cancers, along with chemo line progressions for tumors that are all too common.
The largest oncology network of its kind, powering your research with deep, longitudinal, and continuously refreshed data.
- Real-time access to data on more than 8 million cancer patients in 9 countries
- Inclusive of cancer registry, oncology EMR, and genomic data
- Sourced globally from more than 100 academic and community hospitals
- Define cohorts by primary site, histology, behavior, summary stage, TNM stage, and biomarker
- Rapidly compare outcomes, including survival and time to next treatment, with our built-in analytics
- Connect with the healthcare organizations treating patients of interest, for study site selection and targeted enrollment
Our datasets for breast and lung cancer are available to license now. We are building equally rich datasets for additional indications. Connect with us to learn about our roadmap.
Breast Cancer Dataset
92K
Patients
57
Median age at diagnosis
47K
Received hormone therapy as their first treatment course
5K
Received immunotherapy as first course of therapy
32K
Patients with HER2, ER, and PR receptor status
18K
ER/PR+ HER-
6K
HER2+ patients
5K
Triple negative
Speak with one of our dataset experts. We`ll run counts by biomarker, treatment, or other element to ensure our data answers your question.
Lung Cancer Dataset
67K
Patients
64
Median age at diagnosis
30K
Received hormone therapy as their first treatment course
24K
Received beam radiation
55K
Non-small cell lung cancer patients
8K
Small cell lung cancer patients
29K
Current or prior smoker
1K
Patients with PD-L1 result